Larissa Akemi Kido

Larissa Akemi Kido

Auto-generated profile, based on publicly available information

Larissa Akemi Kido

Research Center Boldrini Children's Center Campinas São Paulo Brazil

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Life Sciences
Verified
Journal Article
Closed access
LKLarissa Akemi Kido
Larissa Akemi Kido
CLCelina de Almeida Lamas
Celina de Almeida Lamas
MJMário Roberto Maróstica Junior
Mário Roberto Maróstica Junior
VCValéria Helena Alves Cagnon
Valéria Helena Alves Cagnon

12 May 2017 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
RSRaquel Frenedoso da Silva
Raquel Frenedoso da Silva
ENEllen Nogueira-Pangrazi
Ellen Nogueira-Pangrazi
LKLarissa Akemi Kido
Larissa Akemi Kido
FMFabio Montico
Fabio Montico
SASarah Arana
Sarah Arana
VCValéria Helena Alves Cagnon
Valéria Helena Alves Cagnon
In recent times, anti-cancer treatments have focused on Fibroblast Growth Factor (FGF) and Vascular-Endothelial Growth Factor (VEGF) pathway inhibitors so as to target tumor angiogenesis and cellular proliferation. One such drug is Nintedanib; the present study evaluated the effectiveness of Nintedanib treatment against in vitro proliferation of human prostate cancer (PCa) cell lines, and growth and progression of different grades of PCa lesions in pre-clinical PCa transgenic adenocarcinoma for the mouse prostate (TRAMP) model. Both androgen-independent (LNCaP) and androgen-dependent (PC3) PCa cell lines were treated with a range of Nintedanib doses for 72 h, and effect on cell growth and expression of angiogenesis associated VEGF receptors was analyzed. In pre-clinical efficacy evaluation, male TRAMP mice starting at 8 and 12 weeks of age were orally-fed with vehicle control (10% Tween 20) or Nintedanib (10 mg/Kg/day in vehicle control) for 4 weeks, and sacrificed immediately after 4 weeks of drug treatment or sacrificed 6–10 weeks after stopping drug treatments. At the end of treatment schedule, mice were sacrificed and ventral lobe of prostate was excised along with essential metabolic organ liver, and subjected to histopathological and extensive molecular evaluations. The total cell number decreased by 56–80% in LNCaP and 45–93% in PC3 cells after 72 h of Nintedanib treatment at 2.5–25 μM concentrations. In pre-clinical TRAMP studies, Nintedanib led to a delay in tumor progression in all treatment groups; the effect was more pronounced when treatment was given at the beginning of the glandular lesion development and continued till study end. A decreased microvessel density and VEGF immunolocalization was observed, besides decreased expression of Androgen Receptor (AR), VEGFR-1 and FGFR-3 in some of the treated groups. No changes were observed in the histological liver analysis. Nintedanib treatment was able to significantly decrease the growth of PCa cell lines and also delay growth and progression of PCa lesions to higher grades of malignancy (without inducing any hepatotoxic effects) in TRAMP mice. Furthermore, it was observed that Nintedanib intervention is more effective when administered during the early stages of neoplastic development, although the drug is capable of reducing cell proliferation even after treatment interruption.

30 June 2020 in Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
LKLarissa Akemi Kido
Larissa Akemi Kido
EHEun-Ryeong Hahm
Eun-Ryeong Hahm
SKSu-Hyeong Kim
Su-Hyeong Kim
ABAndressa Mara Baseggio
Andressa Mara Baseggio
VCValeria Helena Alves Cagnon
Valeria Helena Alves Cagnon
MJMário Roberto Maróstica Junior
Mário Roberto Maróstica Junior
Larissa Akemi Kido, Eun-Ryeong Hahm, Su-Hyeong Kim, Andressa Mara Baseggio, Valeria Helena Alves Cagnon, Shivendra V. Singh, Mário Roberto Maróstica Jr.. J Cancer Prev 2020;25:87-99. https://doi.org/10.15430/JCP.2020.25.2.87

2 August 2021 in Journal of Food Biochemistry
Verified
Journal Article
Closed access
PDF file
ABAndressa Mara Baseggio
Andressa Mara Baseggio
LKLarissa Akemi Kido
Larissa Akemi Kido
JVJULIANE VIGANO
JULIANE VIGANO
MCMara Junqueira Carneiro
Mara Junqueira Carneiro
CLCelina Lamas
Celina Lamas
MJMário Roberto Maróstica Junior
Mário Roberto Maróstica Junior

22 December 2022 in The Prostate
Verified
Journal Article
Closed access
IRIsabela Rossetto
Isabela Rossetto
FSFelipe Santos
Felipe Santos
LKLarissa Kido
Larissa Kido
CLCelina Lamas
Celina Lamas
FMFábio Montico
Fábio Montico
VCValéria Cagnon
Valéria Cagnon

30 September 2022 in Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
LKLarissa Akemi Kido
Larissa Akemi Kido
IRIsabela Maria Urra Rossetto
Isabela Maria Urra Rossetto
ABAndressa Mara Baseggio
Andressa Mara Baseggio
GCGabriela Bortolanca Chiarotto
Gabriela Bortolanca Chiarotto
LALetícia Ferreira Alves
Letícia Ferreira Alves
VCValéria Helena Alves Cagnon
Valéria Helena Alves Cagnon
Larissa Akemi Kido, Isabela Maria Urra Rossetto, Andressa Mara Baseggio, Gabriela Bortolanza Chiarotto, Letícia Ferreira Alves, Felipe Rabelo Santos, Celina de Almeida Lamas, Mário Roberto Maróstica Jr, Valéria Helena Alves Cagnon. J Cancer Prev 2022;27:182-91. https://doi.org/10.15430/JCP.2022.27.3.182